Der Kaninchen Polyklonal anti-VEGFR2/CD309 Antikörper (ABIN115389) detektiert spezifisch VEGFR2/CD309 in IHC (p).
Dieser Antikörper reagiert spezifisch mit Proben aus Human, Maus und Ratte.
VEGFR2
Reaktivität: Human
WB, IHC, ICC
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
Western Blotting. Immunohistochemistry on Paraffin Sections: Use a 1/50-1/100 dilution in an ABC method(incubation time: 30 minutes at room temperature). Formalin fixed paraffin embedded tissue sections require high temperature antigenunmasking with 10 mM citrate buffer, pH 6.0 prior to immunostaining. Recommended positive control: Angiosarcoma. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Lagerung
4 °C
Informationen zur Lagerung
Store the antibody undiluted at 2-8 °C.
Target
VEGFR2/CD309 (VEGFR2)
(VEGF Receptor 2 (VEGFR2))
Andere Bezeichnung
CD309 / VEGFR-2 / Flk-1
Hintergrund
CD309 is a member of a receptor tyrosine kinase family whose activation plays an essential role in a large number of biological processes such as embryonic development, wound healing, cell proliferation, migration and differentiation. Like other growth factor receptors, upon ligand binding VEGF receptor 2 dimerises and is autophosphorylated on multiple tyrosine residues. These sites can be involved in the regulation of kinase activity or serve as binding sites for SH2 and phosphotyrosine binding containing signalling proteins. Phosphorylation of Tyrosines 1054 and 1059 in the activation loop is required for activation of VEGF receptor 2 and its intrinsic tyrosine kinase activity. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.Synonyms: FLK1, KDR, Kinase NYK, Kinase insert domain receptor, Protein-tyrosine kinase receptor Flk-1, VEGF Receptor 2, VEGFR2, Vascular endothelial growth factor receptor 2